EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites36
Patients1032

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	547
New Zealand	198
Finland	106
Switzerland	59
Saudi Arabia	47
Ireland	31
Belgium	27
Slovenia	12
Germany	5
Total	1032